Max Healthcare Institute Ltd.Q3 Headwinds Temporary

Max Healthcare delivered its 21st consecutive quarter of year-on-year growth with gross revenue of ₹2,608 crore, up 10% YoY, despite temporary headwinds.

Operating EBITDA grew 4% to ₹648 crore, though margins compressed 120 bps to 26.1% due to transitory factors including insurance contract disruptions, seasonal softness, payor mix shift toward institutional patients, and pre-commissioning expenses. Management emphasized these challenges are fully resolved, with insurance contracts restored and featuring automatic annual renewal mechanisms. The CGHS tariff revision will deliver a net annual benefit of ₹140 crore from Q1 FY27 after adjustments.

The company maintains strong operational metrics with ARPOB of ₹77,900 (up 3% YoY) and 74% occupancy despite 8% bed capacity expansion. Management outlined an aggressive growth roadmap from current 4,800 beds to 8,000 beds by FY28, with new brownfield capacity already EBITDA and margin accretive. The exceptional performance of Max Dwarka, achieving 75% occupancy and 20% margins within months, prompted Board approval for additional 260-bed expansion, demonstrating strong execution capabilities and positioning the company for sustained growth ahead.